The Alphabet, Astellas, Novartis and WuXi AppTec-backed T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

TScan Therapeutics, a US-based T-cell immunotherapy developer backed by internet and technology group Alphabet and pharmaceutical firms Astellas, Novartis and WuXi AppTec, has filed for an initial public offering (IPO). The company has set a placeholder figure of $100m and intends to float on the Nasdaq Global Market. Morgan Stanley, Jefferies, Cowen and Barclays Capital…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.